J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1194/jlr.M500533-JLR200 on July 21, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M500533-JLR200v1
47/10/2333    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schaap, F. G.
Right arrow Articles by Groen, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schaap, F. G.
Right arrow Articles by Groen, A. K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Lipid Research, Vol. 47, 2333-2339, October 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology


Patient-Oriented Research

Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia

Frank G. Schaap1,*, Melchior C. Nierman{dagger}, Jimmy F. P. Berbée§, Hiroaki Hattori**, Philippa J. Talmud{dagger}{dagger}, Stefan F. C. Vaessen{dagger}, Patrick C. N. Rensen§, Robert A. F. M. Chamuleau*, Jan Albert Kuivenhoven{dagger} and Albert K. Groen*,§§

* Academic Medical Center Liver Center, 1105 BK Amsterdam, The Netherlands
{dagger} Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
§ Department of General Internal Medicine, Endocrinology, and Metabolism, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
** Department of Advanced Medical Technology and Development, BML, Inc., Kawagoe, Saitama 350-1101, Japan
{dagger}{dagger} Department of Medicine, Royal Free and University College Medical School, Rayne Institute, London WC1E 6JF, UK
§§ Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands

Published, JLR Papers in Press, July 21, 2006.

1 To whom correspondence should be addressed. e-mail: f.g.schaap{at}amc.uva.nl


ABSTRACT

The relevance of apolipoprotein A-V (apoA-V) for human lipid homeostasis is underscored by genetic association studies and the identification of truncation-causing mutations in the APOA5 gene as a cause of type V hyperlipidemia, compatible with an LPL-activating role of apoA-V. An inverse correlation between plasma apoA-V and triglyceride (TG) levels has been surmised from animal data. Recent studies in human subjects using (semi)quantitative immunoassays, however, do not provide unambiguous support for such a relationship. Here, we used a novel, validated ELISA to measure plasma apoA-V levels in patients (n = 28) with hypertriglyceridemia (HTG; 1.8–78.7 mmol TG/l) and normolipidemic controls (n = 42). Unexpectedly, plasma apoA-V levels were markedly increased in the HTG subjects compared with controls (1,987 vs. 258 ng/ml; P < 0.001). In the HTG group, apoA-V and TG were positively correlated (r = +0.44, P = 0.02). In addition, we noted an increased level of the LPL-inhibitory protein apoC-III in the HTG group (45.8 vs. 10.6 mg/dl in controls; P < 0.001). The correlation between apoA-V and TG levels in the HTG group disappeared (partial r = +0.09, P = 0.65) when controlling for apoC-III levels. In contrast, apoC-III and TG remained positively correlated in this group when controlling for apoA-V (partial r = +0.43, P = 0.025). Our findings suggest that in HTG patients, increased TG levels are accompanied by high plasma levels of apoA-V and apoC-III, apolipoproteins with opposite modes of action. This study provides evidence for a complex interaction between apoA-V and apoC-III in patients with severe HTG.

Supplementary key words apolipoprotein C-III • apolipoprotein A-V • lipoprotein lipase • enzyme-linked immunosorbent assay

Abbreviations: apoA-V, apolipoprotein A-V; HTG, hypertriglyceridemia, hypertriglyceridemic; MAb, monoclonal antibody; TC, total cholesterol; TG, triglyceride


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
L. Nelbach, X. Shu, R. J. Konrad, R. O. Ryan, and T. M. Forte
Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice
J. Lipid Res., March 1, 2008; 49(3): 572 - 580.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
J. Kahri, J. Fruchart-Najib, N. Matikainen, J.-C. Fruchart, J. Vakkilainen, and M.-R. Taskinen
The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity
Diabetes Care, August 1, 2007; 30(8): 2083 - 2085.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Dichlberger, L. A. Cogburn, J. Nimpf, and W. J. Schneider
Avian apolipoprotein A-V binds to LDL receptor gene family members
J. Lipid Res., July 1, 2007; 48(7): 1451 - 1456.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.